• COMPANY
    Company
  • BUSINESS
    Business
  • NEWS
    News
CONTACT
  • Cn
  • Jp
  • En
        
  • Platform Business Platform Business
  • Sales and Marketing Sales and Marketing
  • New Drug Development New Drug Development
  • COMPANY
  • BUSINESS
    • Platform Business Platform Business
    • Sales and Marketing Sales and Marketing
    • New Drug Development New Drug Development
  • NEWS
CONTACT
  • Cn
  • Jp
  • En
  • TOP
  • News

News

  • 2022.12.29

    Press Release

    Ping An-Shionogi Signs an Agreement with Chia Tai Tianqing Pharmaceutical, a subsidiary of Sino Biopharmaceutical, for Domestic Promotion of Ensitrelvir, a Therapeutic Drug for COVID-19
  • 2022.12.23

    Press Release

    Ping An-Shionogi Signs a License Agreement for Import and Domestic Distribution of Ensitrelvir, a Therapeutic Drug for COVID-19
  • 2022.11.23

    Notice

    Shionogi Announces Xocova® (Ensitrelvir Fumaric Acid) Tablets 125mg Approved in Japan for the Treatment of SARS-CoV-2 Infection, under the Emergency Regulatory Approval System
  • 2022.09.29

    Notice

    Shionogi Announces Achievement of the Primary Endpoint for Ensitrelvir Fumaric Acid (S-217622) in the Phase 3 part of the Phase 2/3 Clinical Trial in Asia
  • 2022.07.04

    Notice

    Ping An-Shionogi Initiates the Submission of the Preparation Materials for New Drug Application for S-217622, a Therapeutic Drug for COVID-19, in China
  • 2021.06.30

    Press Release

    Ping An-Shionogi Initiated a New Collaboration with Ping An-Health for Real World Data (RWD) Collection and Analysis Research
Back to Top

Contact

Inquiry Form
  • WeChat
    WeChat
  • SmartPhone
    Mobile Website Share Website
  • Address Room 602, 6F, 199 Kaibin Rd, Xuhui District, Shanghai

SITEMAP

  • TOP

  • Company

  • Business

    • Platform Business

    • Sales and Marketing

    • New Drug Development

  • News

  • Contact

  • Privacy Policy

  • 沪ICP备2021014256号-1
  • 沪公网安备31010402009250号
  • ©2021 Ping An-Shionogi Co., Ltd.